SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer

Share :
Published: 14 Apr 2026
Views: 141
Rating:
Save
Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China

Prof Yi-Long Wu speaks to ecancer about early-phase results evaluating SHR-A2009, a novel HER3-directed antibody-drug conjugate, in combination with a third-generation EGFR tyrosine kinase inhibitor in patients with EGFR-mutant non-small cell lung cancer.

The combination demonstrated encouraging clinical activity in both previously treated and first-line settings, with particularly strong progression-free survival signals in treatment-naïve patients.

Safety was manageable overall, although some higher-grade adverse events, including interstitial lung disease, were observed and require careful monitoring.

These findings support further development of this combination, with a phase III trial already underway to confirm its potential as a new first-line treatment option in EGFR-mutant lung cancer.

Related Videos

Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC

Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA
Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC ( Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA )
13 Oct 2026

Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC

Prof David Gandara - University of California Davis Comprehensive Cancer Center, Sacramento, USA
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC ( Prof David Gandara - University of California Davis Comprehensive Cancer Center, Sacramento, USA )
28 Sep 2026

T-cell engagers in lung cancer: Strategies to prevent and manage toxicities

Dr Myung-Ju Ahn - Sungkyunkwan University School of Medicine, Seoul, South Korea
T-cell engagers in lung cancer: Strategies to prevent and manage toxicities ( Dr Myung-Ju Ahn - Sungkyunkwan University School of Medicine, Seoul, South Korea )
14 Apr 2026

ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC

Prof Benjamin Besse - Institut Gustave Roussy, Villejuif, France
ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC ( Prof Benjamin Besse - Institut Gustave Roussy, Villejuif, France )
13 Apr 2026

Gotistobart improves survival and response over docetaxel in previously treated squamous lung cancer

Dr Kai He - The Ohio State University Comprehensive Cancer Center, Columbus, USA
Gotistobart improves survival and response over docetaxel in previously treated squamous lung cancer ( Dr Kai He - The Ohio State University Comprehensive Cancer Center, Columbus, USA )
13 Apr 2026

Immunoprevention and early detection of lung cancer in Africa: The LUNG-GUARD Platform

Dr Chiswili Yves Chabu - University of Missouri, Columbia, USA
Immunoprevention and early detection of lung cancer in Africa: The LUNG-GUARD Platform ( Dr Chiswili Yves Chabu - University of Missouri, Columbia, USA )
27 Jan 2026

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo

Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece
Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo ( Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece )
4 Nov 2025

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
20 Oct 2025

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC

Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA
Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC ( Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA )
19 Oct 2025